Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice-Reference-Cited by-同舟云学术

Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice

Published:2005-06-15 Issue:12 Volume:11 Page:4393-4399
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Ma Yan,Lespagnard Laurence,Durbecq Virginie,Paesmans Marianne,Desmedt Christine,Gomez-Galdon Maria,Veys Isabelle,Cardoso Fatima,Sotiriou Christos,Di Leo Angelo,Piccart Martine J.,Larsimont Denis

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment;Breast Cancer Research;2024-06-12

2. Immunohistochemical detection of cancer genetic abnormalities;Pathology - Research and Practice;2024-03

3. In situ HER2 RNA expression as a predictor of pathologic complete response of HER2- positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment;2023-06-26

4. Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer;Cancers;2022-09-21

5. Clinical and Pathologic Features Associated With Invasive Breast Carcinoma with 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0);Archives of Pathology & Laboratory Medicine;2021-09-27